DENTSPLY SIRONA Inc. (XRAY) SEC Filings & Earnings Calls
EquiReason read 16 DENTSPLY SIRONA Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-09 — DENTSPLY SIRONA amended credit and note purchase agreements to increase maximum leverage ratios, add EBITDA addbacks, restrict liens and dividends, and raise interest rates on note.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- 6.8%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
9 Oct 20268-K · 1.01, 2.03DENTSPLY SIRONA amended credit and note purchase agreements to increase maximum leverage ratios, add EBITDA addbacks, restrict liens and dividends, and raise interest rates on notes to maintain covenant compliance.open
Risks flagged
Increased leverage ratios and restricted dividends signal elevated financial risk and potential covenant breach.
“increase the maximum permitted Total Leverage Ratio and the maximum permitted Senior Leverage Ratio... limit restricted payments” · word for word
6 Aug 202610-QDentsply Sirona reported Q2 2026 net sales of $898M, down 4.1% YoY, with gross margin improvement to 54.9%.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Total · Q2-2026 | $898M | -4% y/y |
| Gross Profit · Q2-2026 | $493M | +1% y/y |
| Gross Margin · Q2-2026 | 54.9% | |
| SG&A Expenses · Q2-2026 | $364M | +6% y/y |
| R&D Expenses · Q2-2026 | $45M | +22% y/y |
| Net Sales - Connected Technology Solutions · Connected Technology Solutions · Q2-2026 | $239M | -2% y/y |
| Net Sales - Essential Dental Solutions · Essential Dental Solutions · Q2-2026 | $376M | -3% y/y |
| Net Sales - Orthodontic and Implant Solutions · Orthodontic and Implant Solutions · Q2-2026 | $197M | -13% y/y |
| Net Sales - Wellspect Healthcare · Wellspect Healthcare · Q2-2026 | $86M | +8% y/y |
| Segment Adjusted Operating Income - Connected Technology Solutions · Connected Technology Solutions · Q2-2026 | $-2M | -117% y/y |
Risks flagged
Geopolitical conflict exposure in Israel
“The Company’s operations in Israel consist of two manufacturing facilities for implants products, with one site in northern Israel and one site in southern Israel, both of which remain open and continue to operate normally.” · word for word
Russia cash repatriation restrictions
“Due to currency control measures imposed by the Russian government, which include restrictions on the ability of companies to repatriate or otherwise remit cash from their Russian-based operations to locations outside of Russia, we continue to be limited in our ability to transfer this cash balance out of Russia without incurring substantial costs.” · word for word
Distributor inventory destocking
“We expect changes in the Company’s distribution model, including a reduced emphasis on distributor-held inventory, will likely increase variability in ordering patterns and contribute to fluctuations in net sales and operating income.” · word for word
5 May 20268-K · 2.02Net sales $880M (+0% y/y); GAAP gross margin 48.5; Adjusted gross margin 50.7; Guidance: FY2026 net sales $3.5-$3.6B, adjusted EPS $1.40-$1.50earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $880M | +0% y/y |
| GAAP gross margin · Q1-2026 | 48.5% | |
| Adjusted gross margin · Q1-2026 | 50.7% | |
| Adjusted EBITDA · Q1-2026 | $129M | -23% y/y |
| Adjusted EBITDA margin · Q1-2026 | 14.7% | |
| Adjusted EPS · Q1-2026 | $0.27 | -39% y/y |
| GAAP net loss · Q1-2026 | $-10M | |
| Operating cash flow · Q1-2026 | $40M | |
| Free cash flow · Q1-2026 | $-12M |
Guidance
FY2026 net sales $3.5-$3.6B, adjusted EPS $1.40-$1.50
Reiterated full-year guidance despite weak Q1, expecting momentum to build
Risks flagged
Significant margin compression across all segments
“GAAP gross margin 48.5% vs 53.0% YoY, adjusted EBITDA margin 14.7% vs 19.0%”
Orthodontic and Implant Solutions segment decline
“Orthodontic and Implant Solutions net sales down 8.1% as reported”
5 May 202610-QNet Sales $880M (+0% y/y); Gross Profit Margin 48.5; SG&A as % of Net Sales 39.9open
Figures in the filing · each found in the filing text
| Net Sales · Total · Q1-2026 | $880M | +0% y/y |
| Gross Profit Margin · Total · Q1-2026 | 48.5% | |
| SG&A as % of Net Sales · Total · Q1-2026 | 39.9% | |
| R&D as % of Net Sales · Total · Q1-2026 | 5.0% | |
| Segment Adjusted Operating Income - CTS · Connected Technology Solutions · Q1-2026 | $-6M | -186% y/y |
| Segment Adjusted Operating Income - EDS · Essential Dental Solutions · Q1-2026 | $121M | -10% y/y |
| Segment Adjusted Operating Income - OIS · Orthodontic and Implant Solutions · Q1-2026 | $8M | -78% y/y |
| Segment Adjusted Operating Income - Wellspect · Wellspect Healthcare · Q1-2026 | $23M | -12% y/y |
Risks flagged
Tariff cost pressure on margins
“The decrease was also driven by ... higher tariff costs.”
Geopolitical risk in Israel and Russia
“Net assets within Israel totaled $131 million; net assets in Russia and Ukraine were $89 million, including $53 million cash restricted from repatriation.” · word for word
Distribution model changes causing volatility
“We expect changes in the Company's distribution model, including a reduced emphasis on distributor-held inventory, will likely increase variability in ordering patterns.” · word for word
23 Apr 2026DEF 14AMultiple executive transitions in 2025: new CEO, CFO, CCO appointed; former CEO, CFO, General Counsel departed.open
Figures in the filing · each found in the filing text
| Net Sales · FY2025 | $3.68B | -3% y/y |
| Organic Sales Decrease % · FY2025 | 4.3% | |
| Adjusted EBITDA Margin · FY2025 | 18.1% | |
| GAAP Loss Per Basic Common Share (EPS) · FY2025 | $-3.00 | |
| Adjusted Earnings Per Diluted Common Share (EPS) · FY2025 | $1.60 | -5% y/y |
Risks flagged
Executive turnover risk
“Throughout 2025, the Company experienced several executive transitions.” · word for word
Revenue decline risk
“Net Sales $3,680 $3,793 (3.0%)” · word for word
Organic sales decline risk
“Organic Sales Decrease % (4.3%) (3.5%)”
Byte aligner business suspension risk
“The 2025 organic net sales target was lower than the corresponding 2024 target as a result of the Company's voluntary suspension of sales and marketing of its Byte aligner systems and impression kits.” · word for word
Share dilution risk
“proposed increase of 15,000,000 shares to the 2024 Plan”
26 Feb 202610-KNet loss $-598M; Cash flow from operations $235M; Goodwill and intangible asset impairment charges $650M; Guidance: R&D to increase to ~5% of net sales; restructuring targets $120M annual cost savingsopen
Figures in the filing · each found in the filing text
| Net loss · FY2025 | $-598M | |
| Cash flow from operations · FY2025 | $235M | |
| Goodwill and intangible asset impairment charges · FY2025 | $650M | |
| Annualized cost savings from 2026 Plan · FY2026 | $120M | |
| R&D as % of net sales (planned) · FY2026 | 5.0% |
Guidance
R&D to increase to ~5% of net sales; restructuring targets $120M annual cost savings
Revenue declined, but company is investing in R&D and restructuring for cost savings.
Risks flagged
Cybersecurity and AI-related vulnerabilities
“The 2022 launch of DS Core, our cloud platform that integrates digital dentistry workflows across devices, and the 2024 launch of Primescan 2, a cloud-native intraoral scanner, have introduced new potential vulnerabilities to cyber attacks.” · word for word
Distributor concentration
“Customers that accounted for 10% or more of net sales or accounts receivable for the year ended December 31, 2025 were as follows: Henry Schein, Inc. 13% of net sales.” · word for word
Restructuring execution risk
“We may fail to realize the expected benefits of our strategic initiatives, including executed, announced, or potential future restructuring and other business transformation efforts.” · word for word
26 Feb 20268-K · 2.02Net Sales $961M (+6% y/y); Net Sales $3.68B (-3% y/y); Net (Loss) Attributable to Dentsply Sirona $-146M; Guidance: FY2026 adjusted EPS $1.40-$1.50 vs FY2025 $1.60earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q4-2025 | $961M | +6% y/y |
| Net Sales · FY2025 | $3.68B | -3% y/y |
| Net (Loss) Attributable to Dentsply Sirona · Q4-2025 | $-146M | |
| Net (Loss) Attributable to Dentsply Sirona · FY2025 | $-598M | |
| Adjusted EPS · Q4-2025 | $0.27 | +5% y/y |
| Adjusted EPS · FY2025 | $1.60 | -5% y/y |
| Adjusted EBITDA · Q4-2025 | $135M | +5% y/y |
| Adjusted EBITDA · FY2025 | $667M | +6% y/y |
| Operating cash flow · Q4-2025 | $101M | +16% y/y |
| Operating cash flow · FY2025 | $235M | -49% y/y |
Guidance
FY2026 adjusted EPS $1.40-$1.50 vs FY2025 $1.60
FY2026 outlook implies lower adjusted EPS than FY2025; restructuring and dividend elimination indicate cost-cutting mode
Risks flagged
Goodwill and intangible impairments of $144M net of tax in Q4
“Q4 2025 reported net loss of ($146) million driven by goodwill and intangible impairments of ($144) million, net of tax” · word for word
Dividend elimination signals financial stress and need to conserve cash
“Initiated new capital allocation strategy by eliminating the dividend and redeploying capital toward debt retirement and share repurchases” · word for word
24 Feb 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
Board refreshment may signal need for strategic change; departure of long-serving director could indicate governance transition.
“Willie Deese not seeking reelection after 15 years of service.”
13 Jan 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
Company is executing a Return-to-Growth action plan; no financial details provided
“Board has established a special, ad hoc four-member Growth and Value Creation Committee to oversee execution of the Return-to-Growth action plan” · word for word
25 Nov 20258-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Leadership transition risk; interim CFO appointment may signal ongoing search for permanent CFO.
“Interim CFO appointment; CEO serving as principal financial officer until permanent CFO is named.”
6 Nov 20258-K · 2.02Net Sales $904M (-5% y/y); GAAP Gross Margin 48.8; Adjusted Gross Margin 52.6; Guidance: FY2025 net sales $3.6-$3.7B; constant currency sales -5% to -4%; adjusted EPS ~$1.60earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q3-2025 | $904M | -5% y/y |
| GAAP Gross Margin · Q3-2025 | 48.8% | |
| Adjusted Gross Margin · Q3-2025 | 52.6% | |
| Adjusted EBITDA Margin · Q3-2025 | 18.4% | |
| Adjusted EPS · Q3-2025 | $0.37 | -26% y/y |
| GAAP Net Loss Per Share · Q3-2025 | $-2.14 | |
| FY2025 Adjusted EPS Guidance · FY2025 | $1.60 |
Guidance
FY2025 net sales $3.6-$3.7B; constant currency sales -5% to -4%; adjusted EPS ~$1.60
FY2025 guidance cut significantly; sales decline and margin pressure; transformation plan announced.
Risks flagged
Sales decline, impairment charges, CFO departure, and competitive pressures in dental market.
“Net sales -5% YoY; impairment charges $263M; CFO departed; Return-to-Growth plan indicates significant challenges.”
6 Nov 20258-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
CFO departure creates leadership gap during a period of operational challenges and transformation.
“CFO departed; CEO assumes interim role; search for successor underway.”
6 Nov 202510-QDentsply Sirona reported a significant revenue decline of -5% YoY in Q3 2025, with gross margin contracting 330 bps, driven by Byte suspension, competitive pricing, and distributor destocking, alongside a $253M goodwill impairment.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q3-2025 | $904M | -5% y/y |
| Net Sales · 9M-2025 | $2.72B | -6% y/y |
| Gross Profit Margin · Q3-2025 | 48.8% | |
| Gross Profit Margin · 9M-2025 | 51.4% | |
| Net Sales - Connected Technology Solutions · Connected Technology Solutions · Q3-2025 | $259M | -4% y/y |
| Net Sales - Essential Dental Solutions · Essential Dental Solutions · Q3-2025 | $357M | -3% y/y |
| Net Sales - Orthodontic and Implant Solutions · Orthodontic and Implant Solutions · Q3-2025 | $205M | -15% y/y |
| Net Sales - Wellspect Healthcare · Wellspect Healthcare · Q3-2025 | $83M | +16% y/y |
| Net Sales - United States · Q3-2025 | $291M | -22% y/y |
| Net Sales - Europe · Q3-2025 | $382M | +10% y/y |
Risks flagged
Byte business suspension
“lower volumes of clear aligners in the United States, primarily related to the suspension of Byte sales” · word for word
Distributor destocking
“Sales for CAD/CAM products were negatively impacted by a lower quarterly increase in distributor inventory levels of approximately $20 million in the three months ended September 30, 2025, compared to approximately $36 million in the three months ended September 30, 2024.” · word for word
Competitive pricing pressure
“The net sales decrease on a constant currency basis for the three and nine months ended September 30, 2025 was primarily due to lower volumes of CAD/CAM products, particularly in the United States, driven in part by competitive pressures including pricing.” · word for word
Goodwill impairment risk
“For the three months ended September 30, 2025, the Company recorded pre-tax goodwill impairment charges of $253 million for the Implant & Prosthetic Solutions reporting unit” · word for word
DENTSPLY SIRONA Inc. — questions
- What did DENTSPLY SIRONA Inc. file recently?
- 16 SEC filings in the last 12 months. Latest: 8-K on 2026-10-09 — DENTSPLY SIRONA amended credit and note purchase agreements to increase maximum leverage ratios, add EBITDA addbacks, restrict liens and dividends, and raise interest rates on notes to maintain covenant compliance.
Every figure on this page comes from DENTSPLY SIRONA Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.